Cardioembolic sources account for 20-30% of ischaemic strokes and are important to identify considering their prognostic and therapeutic implications. During the past years, new developments have been made in the cardiac diagnostic evaluation and management of patients with ischaemic stroke, especially regarding strokes of unknown aetiology. These recent advances have had a major impact on our understanding of embolic strokes, their diagnostic work-up, and clinical management. Herein, we propose a cardiac diagnostic work-up scheme for patients with ischaemic stroke from definite cardioembolic sources and embolic strokes of undetermined source.
Introduction
Ischaemic stroke is among the leading causes of death and disability worldwide. 1 Identification of underlying aetiologies is of great importance in order to optimally prevent stroke recurrence. Cardioembolic and unknown sources account for 20-30% and 30-40% of ischaemic strokes, respectively. 2, 3 Cardioembolic stroke generally carries a worse prognosis with respect to disability, mortality, and both early and long-term recurrence of stroke compared to other etiologies. 4, 5 The cardiac diagnostic assessment is, therefore, essential in identifying a large proportion of ischaemic strokes with a wide range of aetiologies. During the past years, new developments have been made in the cardiac diagnostic evaluation of cardioembolic and unknown sources with therapeutic implication, especially regarding the long-term secondary prevention of stroke. This paper aims to review the aforesaid developments and propose a cardiac diagnostic work-up scheme based on the most recent evidence of diagnostic and management strategies.
Definite cardioembolic source
Although a number of cardiac conditions have been proposed as potential sources of embolism, definitive cardioembolic sources have well-established pathophysiological links to stroke and are associated with increased stroke risk. 6 This group consists of atrial fibrillation (AF), whether recurrent or permanent, atrial flutter, intracardiac thrombus, prosthetic valve, vegetations, rheumatic valvular disease (mitral stenosis), atrial myxoma or other cardiac tumors, or recent (within 4 weeks) myocardial infarction (Table 1, Figure 1 ). Diagnosing a definite cardioembolic source in patients with ischaemic stroke generally requires a different therapeutic strategy such as the prescription of anticoagulation, compared to standard stroke management (risk factor control and antiplatelet therapy). 7 Therefore, identifying a definite cardioembolic source is essential in the diagnostic work-up of patients with suspected embolism. The majority of definite cardioembolic sources can be accurately diagnosed with medical history, physical examination, laboratory testing, 12-lead electrocardiogram (ECG), heart rhythm monitoring (in-hospital telemetry, ambulant 24-48 h Holter), and transthoracic echocardiography (TTE). 8 Left ventricular (LV) thrombus is a frequent finding in patients with acute myocardial infarction, which can mostly be detected by TTE. 9 Current guidelines recommend 3 months of anticoagulation in four categories of patients with ischaemic stroke or transient ischaemic attack (TIA): (i) acute myocardial infarction with LV thrombus (Class I, level C); (ii) acute myocardial infarction with anteroapical wall-motion abnormalities and LV ejection fraction < 40% (Class IIb, level C); (iii) anterior ST-elevated acute myocardial infarction with anteroapical akinesis or dyskinesis without demonstrable LV thrombus (Class IIb; level C); (iv) isolated LV thrombus (Class I; level C). 7 Regarding anti-thrombotic therapy in patients with dilated cardiomyopathy (LV ejection fraction <35%) or restrictive cardiomyopathy without intracardiac thrombus, it is yet uncertain as to whether antiplatelet therapy or anticoagulation is more effective for prevention of recurrent stroke. 7, 10, 11 Thrombus in the left atrial appendage or left atrium is strongly associated with ischaemic stroke and is most commonly identified in patients with AF, LV dysfunction, mitral valve stenosis, or a prosthetic mitral valve. 12 In contrast, in the absence of such a clinical setting, isolated left atrial appendage/left atrial thrombus is exceedingly rare. 12 Thus, additional transoesophageal echocardiography (TEE) with its superior sensitivity and specificity is rarely necessary in the diagnosis and management of patients with left atrial appendage/left atrial thrombus and ischaemic stroke.
In patients with prosthetic valves and suspicion of valve thrombosis, TTE should be used as a first diagnostic tool to evaluate valve morphology and haemodynamics. 13 As a diagnostic follow-up, TEE, cinefluoroscopy, or computerized tomography (CT) should be conducted to assess the presence and size of thrombus and valve motion. Stroke management of patients with prosthetic valves consists of standard management of stroke (risk factor control and antiplatelet therapy) and of the prosthetic valve and thrombus (optimization of anticoagulation control, surgery, or thrombolysis). 7, 13, 14 Infective endocarditis, whether or not it involves a prosthetic valve, is clinically diagnosed with the Duke criteria. 15 When infective endocarditis is clinically suspected, TTE is the first recommended diagnostic modality, due to its non-invasive nature combined with its ability to provide essential information in diagnosing and assessing infective endocarditis severity. 8, 16 TEE should be considered as the next diagnostic step in cases where either TTE findings are negative yet the clinical suspicion for infective endocarditis is high, when infective endocarditis is suspected in patients with prosthetic valves, or to further characterize infective endocarditis when the TTE is positive. Cardiac masses such as myxoma and papillary fibroelastoma are often asymptomatic and can be detected by TTE. Once identified, therapeutic strategies include surgery or anticoagulation. 8 In summary, medical history, 12-lead ECG, rhythm monitoring and TTE are essential in assessing most definite cardioembolic sources ( Figure 2) . 7, 17, 18 Despite its diagnostic superiority, TEE rarely leads to a change in therapy, thereby limiting its practical utility in guiding therapy. Therefore, we do not recommend the initial or routine use of TEE to detect definite cardioembolic sources, when diagnostic TTE is reasonably expected to resolve diagnostic and management concerns. TEE or other diagnostic modalities (e.g. magnetic resonance imaging; MRI, CT) should be performed as a second step if TTE is non-diagnostic and when findings may alter therapeutic decisions in conditions such as infective endocarditis or thrombosis on prosthetic valve.
Embolic stroke of undetermined source
Despite extensive diagnostic work-up, 30-40% of ischaemic strokes are of unknown source and are referred to as cryptogenic strokes.
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The definition of cryptogenic stroke varies among different classification schemes and hinders defining optimal diagnostic work-up and treatment strategies. The lack of consensus for cryptogenic stroke has prompted proposal of a new term called 'Embolic strokes of undetermined source' (ESUS) by the Cryptogenic Stroke/ESUS International Working Group in order to clarify and replace the old and divided definition of cryptogenic stroke. 19 Since embolic sources are therapeutically relevant to cardiologists, we will discuss recent updates in cardiac diagnostics for detecting ESUS ( Table 1) .
Silent atrial fibrillation
Silent AF is undetected paroxysmal AF without symptoms. Silent AF is a crucial diagnosis to exclude due its potential association with AF, which has strong association with ischaemic stroke, therapeutic implications for secondary prevention, and greater stroke severity with higher mortality compared to other types of ischaemic stroke. 7, 20, 21 Recent studies show that prolonged rhythm monitoring beyond the standard ECG and 24 h-Holter enhances the diagnostic yield in identifying silent AF. 22 Guidelines from 2014 indicate that prolonged 
rhythm monitoring with a 30-day Holter is reasonable to detect silent AF in patients with ESUS within 6 months of the index stroke or TIA event. 7 Two large prospective randomized studies, CRYSTAL-AF and EMBRACE trials demonstrated that prolonged monitoring with insertable cardiac monitors or external loop recorders outperform conventional 24-h Holter monitoring in the detection of silent AF ( Table 2) . 23, 24 The prevalence of silent AF detected by insertable cardiac monitor vs. 24-h Holter monitoring was 3.7% vs. 0.5% at 1 month, 12.6% vs. 2% at 1 year, and 30% vs. 3% at 3 years. The external loop recorder identified silent AF in 16.1% at 30 days compared to 3.2% with 24-h Holter monitoring. 23, 24 Patients with silent AF who present with a stroke are necessarily in a high-risk category for recurrent stroke (i.e. CHA2DS2-VASc score-2). Proposed risk factors for silent AF in patients with ESUS that can be easily detected in a routine clinical setting, include left atrium dilatation, 25 increased level of brain natriuretic protein (BNP) and the N-terminal pro-BNP 26, 27 and excessive supraventricular ectopic activity. 25, 28 In 2009, the Score for the Targeting of AF was proposed using four items (i.e. age >62 years, National Institutes of Health Stroke Scale 8, left atrium dilatation, and absence of symptomatic extracranial stenosis 50% or clinical-radiological lacunar syndrome) based on risk associations from 456 patients with ischaemic stroke. 29 While sensitivity and specificity values of 79-89% and 74-88% in detecting AF were reported, its predictive value has not been validated. 30 In addition to questions regarding optimal duration of monitoring, monitoring methods, and subgroups to target, the significance of brief episodes of silent AF remains to be elucidated and the impact of anticoagulation has yet to be demonstrated. The threshold of silent AF duration associated with recurrent stroke risk remains ambiguous. While multiple studies have shown that brief episodes of silent AF identified by cardiac implantable electronic device were associated with increased risk of stroke, [31] [32] [33] thresholds have ranged from 5 min to 24 h. 34 Moreover, definitions for silent AF have varied among studies (atrial tachycardia to AF), further obscuring uniform conclusions. Finally, despite the observed positive correlation between brief silent AF and stroke risk, causation has not been established. 35 Temporal proximity between silent AF and stroke is highly variable, raising the possibility that brief episodes of silent AF may be a marker of more prolonged episodes of sufficient duration to result in embolic strokes or, alternatively, that they are simply associated with other strokerelated co-morbidities. An ongoing international collaborative metaanalysis with the Virtual International Cardiovascular and Cognitive Trials Archive-Atrial Fibrillation will hopefully shed light on the clinical relevance of cardiac implantable electronic device-detected brief silent AF and the associated risk for stroke. 36 In view of these considerations, it is reasonable to routinely perform prolonged rhythm monitoring (e.g. at least 30 days) in patients within 6 months of the index ESUS, pending further data. Although the clinical significance of very brief episodes of silent AF remains unclear, when an episode of silent AF is identified in the context of an ESUS (CHA2DS2-VASc score 2), it is reasonable to recommend more intense follow-up and prolonged rhythm monitoring of these patients considering that silent AF can transform into overt AF over time. 37 Additional evidence is required to provide definitive guidance regarding optimal duration of monitoring, monitoring method, silent AF duration threshold, and subgroups who may or may not benefit from prolonged monitoring and change to anticoagulation.
Patent foramen ovale
The prevalence of patent foramen ovale (PFO) in patients with ESUS is higher than in the general population (38% vs. 24%). 38 A PFO may result in paradoxical embolization from caval venous blood flow to the systemic circulation by means of right-to-left shunting across the atrial septum ( Figure 1) . Coexisting anatomical features such as large PFO size and associated atrial septal aneurysms may increase PFO thrombogenicity. 39 Current guidelines favour pharmacological therapy alone over percutaneous PFO closure in association with pharmacological therapy for the secondary prevention ESUS in the setting of a PFO. Three randomized controlled trials have compared percutaneous PFO closure with medical therapies in adults with ESUS, i.e. CLOSURE, RESPECT, and PC ( Table 2 ). All three trials failed to show superiority of PFO closure in intention-to-treat analyses of their primary end points. [40] [41] [42] Interpretation of results has remained contro- . CLOSURE data may also be interpreted as supporting potential benefit of PFO closure in these patient subgroups, as well as younger patients (<45 years) without vascular risk factors and those with cortical infarcts. The negative trial results may reflect a lack of efficacy of percutaneous PFO closure or insufficient statistical power due to lower than anticipated event rates. The trials have generally favoured an older patient population, thereby obscuring generalizability to younger stroke patients. Also, non-standardized medical therapy in Medical therapy remains advocated as the de facto approach to treatment in patients with cryptogenic stroke and PFO, in accordance with the AHA/ASA guidelines which only recommend PFO closure in the presence of deep venous thrombosis (Class IIb; level C). 7 Patients with ischaemic stroke and PFO who have no indication for anticoagulation therapy otherwise, are recommended to receive antiplatelet therapy (Class I; level B). 7, 48 It remains under debate whether PFO closure may outperform medical therapy in highly selected patient subgroups. The Risk of Paradoxical Embolism (RoPE) score is presently the only available risk stratification tool for PFO-attributable stroke (area under receiver operating curve ¼ 0.68) to help identify high-risk PFO. 49 However, it has not been validated in prospective studies yet and evidence suggests that patients with a high likelihood of PFOattributable risk of stroke have the lowest rates of recurrent events without closure. 50 Some experts recommend to consider percutaneous PFO closure in patients with a high RoPE score and presence of at least one pre-determined clinical risk factor for recurrent stroke since it is an easily performed and safe procedure. 51 These PFOattributable risk factors include an atrial septal aneurysm, history of deep venous thrombosis, pulmonary embolism and/or thrombophilia, Valsalva-associated embolic events, ischaemic events on arousal, long travel or immobilization-associated event, or simultaneous systemic and pulmonary event.
Complex aortic atherosclerosis
Atherosclerotic plaques are the most common independent predictors of stroke arising from the aorta, more so in the case of aortic wall thickness (including the plaque) 4 mm, the so-called 'complex aortic plaque' (RR 3. 53 ESUS in patients with large and complex plaques is suspected to be of thromboembolic origin, with an association that remains despite medical therapy. 54 Transthoracic echocardiography has a low sensitivity for detecting aortic plaques, although these may occasionally be seen. TEE is the echocardiographic preferred method to evaluate aortic sources of emboli in general, although it may not always visualize the aortic channel sufficiently. CT and MRI are the optimal imaging modalities to overcome these short-comings.
Current American guidelines recommend antiplatelet therapy for ischaemic stroke and evidence of aortic arch atheroma (Class I, level A). 7 The long-awaited ARCH trial-randomizing aspirin plus clopidogrel against warfarin, was discontinued before reaching statistical power ( Table 2) . Nevertheless, a non-significantly lower event rate of recurrent stroke, myocardial infarction, peripheral embolism and vascular death was found in the antiplatelet group compared to the warfarin arm (7.6% vs. 11.3%, HR 0.65 [0.32-1.30], P ¼ 0.2). Supported by an additional significant reduction in vascular death compared to warfarin use, the ARCH trial results suggest a preference for antiplatelet therapy over anticoagulation. 55 In conclusion, routine imaging of complex aortic atherosclerosis is not recommended as it will not change standard stroke therapy.
Other potential cardioembolic source
Other potential cardioembolic sources include relatively prevalent conditions associated with a modest risk for stroke (i.e. <2% annual primary risk for stroke 6 ). These include mitral valve disease (prolapse, annular calcification, and valve strands), aortic valve disease (sclerosis, stenosis, and regurgitation), left atrial smoke, LV aneurysm without thrombus, and atrial septal aneurysm (Table 1, Figure 1) . 6 It remains uncertain whether these diagnoses are causally associated with ischaemic stroke or rather reflect complex correlations with comorbidities. Furthermore, there is no evidence that change in conventional stroke therapy will improve clinical outcomes such as mortality and recurrence of ischaemic stroke. Accordingly, current guidelines recommend conventional stroke management for some of these diagnoses and do not comment on others. 7 In conclusion, despite the availability of excellent diagnostic modalities to identify these conditions, 8 it is not recommended to routinely screen for these diagnoses since doing so is unlikely to alter therapy.
Future implications Rhythm monitor devices
Several ongoing randomized studies are investigating optimal monitoring strategies for detecting silent AF in patients with ischaemic stroke and no history of AF ( Table 3) . STROKE-AF and SAFFO are prospective randomized trials comparing insertable cardiac monitors to standard monitoring after ischaemic stroke 56, 57 The PER-DIEM study is assessing the cost-effectiveness of 1 year monitoring with an insertable cardiac monitor vs. a 30-day event-triggered external loop recorder in patients with ESUS. 58 MOBILE AF is comparing the 1-year use of a mobile ECG device (twice a day or when symptoms occur) with 7-day Holter monitoring. 59 MonDAFIS aims to investigate the therapeutic implication of ECG monitoring for a maximum of 7 days vs. standard monitoring. 60 Two randomized trials are designed to assess the relationship between the cardiac implantable electronic device-detected brief silent AF, risk for stroke, and the therapeutic implications. ARTESiA and NOAH trials are comparing the efficacy of aspirin vs. apixaban and edoxaban, respectively, on thromboembolic events in patients with cardiac implantable electronic device-detected silent AF and additional risk factors for stroke.
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PFO closure
Ongoing studies are addressing whether there is a role for PFO closure in cryptogenic stroke as well as the appropriate choice of closure device ( Table 3) . The CLOSE trial (900 patients) is comparing anticoagulation in addition to several PFO closure devices against antiplatelet therapy,
with stroke as the primary endpoint during a follow-up of 2-9 years. 63 The Gore REDUCE trial randomized 664 patients to PFO closure with the Gore (HELEX) Septal Occluder in combination with antiplatelet therapy vs. antiplatelet therapy alone. 64 Freedom from stroke and imaging-confirmed TIA is being assessed over a minimum of 2 years of follow-up. Finally, DEFENCE-PFO (210 patients, still recruiting) is randomizing patients with ESUS to the Amplatzer PFO Occluder vs. standard medical therapy for a composite of stroke, vascular death, and TIMI-major bleeding within 2 years. 65 Some of the limitations discussed in the prior randomized trials of percutaneous PFO closure are applicable to ongoing trials. These include a control arm that does not differentiate between anticoagulation and antiplatelet therapy and low anticipated event rates. These trials are likely to complement current insights rather than revolutionize the treatment of PFO in cryptogenic stroke. The therapeutic recommendation for PFO and ESUS now primarily favours medical therapy with exception to PFO patients with stroke and simultaneous occurrence of deep venous thrombosis, or pulmonary embolism.
Non-vitamin K antagonist oral anticoagulants
In light of efforts to create consensus in defining ischaemic stroke of unknown source, the 'positively defined' term ESUS has recently been proposed to reflect the hypothesis that most unknown sources of stroke are embolic and are either cardiogenic, arteriogenic, or paradoxical. 19 Currently, ESUS is largely managed by conventional stroke therapy without previous trials defining optimal care. 7 The ESUS group has contended that emboli consist primarily of thrombus, which suggests that anticoagulants are likely to be more effective than antiplatelet agents for secondary prevention. Three large randomized controlled trials were launched to evaluate secondary prevention therapy for ESUS, comparing non-vitamin K antagonist oral anticoagulants to antiplatelet therapy ( Table 3) . RE-SPECT ESUS, NAVIGATE ESUS, and ATTICUS trials will compare dabigatran, rivaroxaban, and apixaban, respectively, to aspirin in patients with ESUS.
66-68
Diagnostic work-up and recommendation
After the initial acute management of patients with ischaemic stroke, the first step in the cardiac diagnostic work-up is to estimate the probability of a definite cardioembolic source identified by medical history, physical examination, initial neurovascular imaging (CT, MRI), laboratory testing, 12-lead ECG, and in-hospital telemetry ( Figure  3) . 4, 69 Clinical signs such as sudden maximal neurologic deficits at onset of stroke, decreased level of consciousness at onset, Wernicke's aphasia or global aphasia without hemiparesis, concurrent systemic embolism, rapid regression of neurological deficit, and onset after a Valsalva-provoking activity can raise suspicion for a cardioembolic source. Other signs may be present on neurovascular imaging such as infarcts in multiple territories (e.g. carotid and middle cerebral artery distribution territories) or massive single large striatocapsular or multiple infarcts in the middle cerebral artery, or bihemispheric combined anterior and posterior circulation or bilateral or multilevel posterior infarcts. When there is a clinical suspicion for a definite cardioembolic source after the initial acute assessment, the next step is to perform TTE and 24-h Holter to assess structural and arrhythmic heart disease. These diagnostic modalities will exclude most cardioembolic sources. In the absence of a lacunar stroke, patients are referred to appropriate specialists to rule-out significant extracranial or intracranial atherosclerosis and other specific causes (e.g. arteritis, dissection, migraine/vasospasms, and drug misuse).
In the absence of an identified cause, cardiologists can proceed with further evaluation for ESUS, which considers the possibility of a PFO-related stroke and silent AF. Suspicion of paradoxical emboli may be heightened in, e.g. very young patients with an atrial septal aneurysm, history of deep venous thrombosis, pulmonary embolism, and thrombophilia. TTE with bubble contrast may be considered if results are likely to influence therapy. Pending definitive evidencebased guidance, prolonged rhythm monitoring for at least 30 days appears sensible within 6 months of the index stroke in all patients with ESUS. It is most likely to yield a diagnosis of silent AF in patients 55 years and older and in those with high-risk features such as National Institutes of Health Stroke Scale 8
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, left atrium dilatation (e.g. >45 mm) 25 , increased BNP (e.g. >65.0 pg/ml) 26 or NT-pro-BNP levels (e.g. >304 pg/ml) 27 , and excessive supraventricular ectopic activity (e.g. presence of any episode of 20 supraventricular extrasystoles with an accelerated cycle length lasting >30 s on 24 hHolter, >500 atrial premature beats/24 h).
25,28
Conclusions
Cardioembolic sources and ESUS are common aetiologies in ischaemic stroke that demand a thorough and therapeutically relevant cardiac diagnostic work-up. Over the past years, new insights have led 
to changes in the diagnostic work-up with therapeutic implications. Medical history, physical examination, laboratory testing, ECG, 24-h Holter monitoring, and TTE are the cornerstone of the cardiac diagnostic work-up. Cumulative evidence now supports the introduction of prolonged rhythm monitoring in diagnostic work-up of ESUS. Although many uncertainties regarding ESUS remain, ongoing studies are addressing key care-limiting questions and will enhance our understanding of the pathophysiology of embolic stroke, clinical outcomes, and best diagnostic and management approaches.
